S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
CGC   21.88 (-1.93%)
NVDA   294.07 (-4.74%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
CGC   21.88 (-1.93%)
NVDA   294.07 (-4.74%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
CGC   21.88 (-1.93%)
NVDA   294.07 (-4.74%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
CGC   21.88 (-1.93%)
NVDA   294.07 (-4.74%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
Log in

NYSE:TARO - Taro Pharmaceutical Industries Stock Price, Forecast & News

$73.24
+0.29 (+0.40 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$72.09
Now: $73.24
$73.47
50-Day Range
$72.50
MA: $81.10
$89.13
52-Week Range
$72.04
Now: $73.24
$109.42
Volume25,844 shs
Average Volume44,384 shs
Market Capitalization$2.80 billion
P/E Ratio11.34
Dividend YieldN/A
Beta0.6
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone972-4847-5700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$669.89 million
Cash Flow$7.88 per share
Book Value$54.07 per share

Profitability

Net Income$281.78 million

Miscellaneous

Employees1,464
Market Cap$2.80 billion
Next Earnings Date5/27/2020 (Estimated)
OptionableOptionable

Receive TARO News and Ratings via Email

Sign-up to receive the latest news and ratings for TARO and its competitors with MarketBeat's FREE daily newsletter.


Taro Pharmaceutical Industries (NYSE:TARO) Frequently Asked Questions

What is Taro Pharmaceutical Industries' stock symbol?

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) issued its quarterly earnings results on Monday, February, 3rd. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.54 by $0.22. The business had revenue of $147.68 million for the quarter, compared to the consensus estimate of $172 million. Taro Pharmaceutical Industries had a return on equity of 12.45% and a net margin of 38.24%. View Taro Pharmaceutical Industries' Earnings History.

When is Taro Pharmaceutical Industries' next earnings date?

Taro Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Wednesday, May 27th 2020. View Earnings Estimates for Taro Pharmaceutical Industries.

What price target have analysts set for TARO?

1 analysts have issued twelve-month price targets for Taro Pharmaceutical Industries' stock. Their forecasts range from $94.00 to $94.00. On average, they expect Taro Pharmaceutical Industries' stock price to reach $94.00 in the next year. This suggests a possible upside of 28.3% from the stock's current price. View Analyst Price Targets for Taro Pharmaceutical Industries.

What is the consensus analysts' recommendation for Taro Pharmaceutical Industries?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Taro Pharmaceutical Industries.

Has Taro Pharmaceutical Industries been receiving favorable news coverage?

Media coverage about TARO stock has trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Taro Pharmaceutical Industries earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the stock's share price in the next several days. View News Stories for Taro Pharmaceutical Industries.

Are investors shorting Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 154,900 shares, a decrease of 5.1% from the January 15th total of 163,200 shares. Based on an average daily volume of 77,100 shares, the days-to-cover ratio is currently 2.0 days. Currently, 1.7% of the company's shares are short sold. View Taro Pharmaceutical Industries' Current Options Chain.

Who are some of Taro Pharmaceutical Industries' key competitors?

What other stocks do shareholders of Taro Pharmaceutical Industries own?

Who are Taro Pharmaceutical Industries' key executives?

Taro Pharmaceutical Industries' management team includes the folowing people:
  • Mr. Uday V. Baldota, CEO & Director (Age 49)
  • Mr. Mariano Balaguer, CFO, Chief Accounting Officer & VP (Age 46)
  • Mr. Itamar Karsenti, VP & Head of Global Operations (Age 47)
  • Mr. Itzik Baruch, VP of Technical Services (Age 56)
  • Dr. Roman Kaplan Ph.D., VP of Scientific and Technical Compliance Mang. (Age 72)

Who are Taro Pharmaceutical Industries' major shareholders?

Taro Pharmaceutical Industries' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (1.89%), Renaissance Technologies LLC (1.61%), Krensavage Asset Management LLC (0.89%), Acadian Asset Management LLC (0.86%), CLARET ASSET MANAGEMENT Corp (0.22%) and Brandes Investment Partners LP (0.21%).

Which major investors are selling Taro Pharmaceutical Industries stock?

TARO stock was sold by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Sei Investments Co., Geode Capital Management LLC, Oxford Asset Management LLP, California Public Employees Retirement System, Freestone Capital Holdings LLC, CLARET ASSET MANAGEMENT Corp and Acadian Asset Management LLC.

Which major investors are buying Taro Pharmaceutical Industries stock?

TARO stock was bought by a variety of institutional investors in the last quarter, including Krensavage Asset Management LLC, Renaissance Technologies LLC, Brandes Investment Partners LP, Jane Street Group LLC, Hotchkis & Wiley Capital Management LLC, Bank of New York Mellon Corp, Algert Global LLC and Group One Trading L.P..

How do I buy shares of Taro Pharmaceutical Industries?

Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Taro Pharmaceutical Industries' stock price today?

One share of TARO stock can currently be purchased for approximately $73.24.

How big of a company is Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries has a market capitalization of $2.80 billion and generates $669.89 million in revenue each year. The company earns $281.78 million in net income (profit) each year or $7.23 on an earnings per share basis. Taro Pharmaceutical Industries employs 1,464 workers across the globe.View Additional Information About Taro Pharmaceutical Industries.

What is Taro Pharmaceutical Industries' official website?

The official website for Taro Pharmaceutical Industries is http://www.taro.com/.

How can I contact Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at 972-4847-5700 or via email at [email protected]


MarketBeat Community Rating for Taro Pharmaceutical Industries (NYSE TARO)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  238 (Vote Outperform)
Underperform Votes:  287 (Vote Underperform)
Total Votes:  525
MarketBeat's community ratings are surveys of what our community members think about Taro Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TARO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TARO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel